Viimane versioon :
03/05/2024
Analgeetikum   Morphine sulfate  
Süsteravim
Salv Suukaudne lahus
Stabiilsus lahustes Stabiilsust mõjutavad tegurid Stabiilsust mõjutavad faktorid Sobimatus Manustamis viis Viited Pdf
   Keemiline struktuur  

Kaubanduslikud nimed erinevates maades   Kaubanduslikud nimed erinevates maades     

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Dimor F Brasiilia
Duramorph Ameerika ühendriigid
Infumorph Ameerika ühendriigid
Miniject Morphine Suurbritannia
Morphine Kanada
Morphine sulfate Lavoisier Prantsusmaa
Viited   Süsteravim   Viited : Morphine sulfate  
Tüüp Avaldamine
3 Ajaleht Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
6 Ajaleht Trissel LA, Xu QA, Martinez JF, Fox JL.
Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C.
Am J Hosp Pharm 1994 ; 51: 2138-2142.
8 Ajaleht Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER.
Compatibility of esmolol hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 368-371.
57 Ajaleht Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
58 Ajaleht Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161.
59 Ajaleht Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62 Ajaleht Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
64 Ajaleht DiStefano JE, Outman WR.
Additional data on visual compatibility of foscarnet sodium with morphine sulfate.
Am J Hosp Pharm 1992 ; 49: 1672.
65 Ajaleht Duafala ME, Kleinberg ML, Nacov C, Flora KP, Hines J, Davis K, McDaniel A, Scott D.
Stability of morphine sulfate in infusion devices and containers for intravenous administration.
Am J Hosp Pharm 1990 ; 47: 143-146.
73 Ajaleht Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
81 Ajaleht Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 Ajaleht Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
86 Ajaleht Johnson CE, Bhatt-Mehta V, Mancari SC, McKown JA.
Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration.
Am J Hosp Pharm 1994 ; 51: 2812-2815.
91 Ajaleht Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
93 Ajaleht Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99 Ajaleht Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
115 Ajaleht Nahata MC, Morosco RS, Hipple TF.
Stability of morphine sulfate in bacteriostatic 0.9% sodium chloride injection stored in glass vials at two temperatures.
Am J Hosp Pharm 1992 ; 49: 2785-2786.
116 Ajaleht Stiles ML, Tu YH, Allen LV Jr.
Stability of morphine sulfate in portable pump reservoirs during storage and simulated administration.
Am J Hosp Pharm 1989 ; 46: 1404-1407.
117 Ajaleht Vecchio M, Walker SE, Iazzetta J, Hardy BG.
The stability of morphine intravenous infusion solutions.
Can J Hosp Pharm 1988 ; 41: 5-9.
119 Ajaleht Strong ML, Schaaf LJ, Pankaskie MC, Robinson DH.
Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devices.
J Clin Pharm Ther 1994 ; 19: 361-369.
120 Ajaleht Walker SE, Coons C, Matte D, DeAngelis C, Iazzetta J, Kolos C, Birkhans B.
Hydromorphone and morphine stability in portable infusion pump cassettes and minibags.
Can J Hosp Pharm 1988 ; 41: 177-182.
121 Ajaleht Walker SE, Iazzetta J, Lau DWC.
Stability of sulfite free high potency morphine sulfate solutions in portable infusion pump cassettes.
Can J Hosp Pharm 1989 ; 42: 195-200.
122 Ajaleht Grassby PF, Hutchings L.
Factors affecting the physical and chemical stability of morphine sulphate solutions stored in syringes.
Int J Pharm Pract 1993 ; 2: 39-43.
129 Ajaleht Smythe M, Malouf E.
Visual compatibility of insulin with secondary intravenous drugs in admixtures.
Am J Hosp Pharm 1991 ; 48: 125-126.
169 Ajaleht Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Ajaleht Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
198 Ajaleht Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
199 Ajaleht Hassan E, Leslie J, Martir-Herrero ML.
Stability of labetalol hydrochloride with selected critical care drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 2143-2145.
218 Ajaleht Vogt C, Ruggaber S.
Compatibility of magnesium sulfate and morphine sulfate in 0.9% sodium chloride injection.
Am J Hosp Pharm 1993 ; 50: 2311.
220 Ajaleht Johnson CE, Christen C, Perez MM, Ma M.
Compatibility of bupivacaine hydrochloride and morphine sulfate.
Am J Health-Syst Pharm 1997 ; 54: 61-64.
221 Ajaleht Neels JT.
Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate.
Am J Hosp Pharm 1992 ; 49: 2149.
240 Ajaleht Lam XM, Ward CA, de C du M?e CPR.
Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy.
Am J Health-Syst Pharm 1995 ; 52: 1904-1909.
244 Ajaleht Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Ajaleht Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Ajaleht Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Ajaleht Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 Ajaleht Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
257 Ajaleht Hunt-Fugate AK, Hennessey CK, Kazarian CM.
Stability of fluconazole in injectable solutions.
Am J Hosp Pharm 1993 ; 50: 1186-1187.
266 Ajaleht Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
295 Ajaleht Yamashita SK, Walker SE, Choudhury T, Iazzetta J.
Compatibility of selected critical care drugs during Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299 Ajaleht Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Ajaleht Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Ajaleht Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Ajaleht Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
314 Ajaleht Chiu MF, Schwartz ML.
Visual compatibility of injectable drugs used in the intensive care unit.
Am J Health-Syst Pharm 1997 ; 54: 64-65.
315 Ajaleht Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316 Ajaleht Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
319 Ajaleht Hadzija BW, Lubarsky DA.
Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia.
Am J Health-Syst Pharm 1995 ; 52: 997-999.
334 Ajaleht Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Ajaleht Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
336 Ajaleht Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Ajaleht Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
340 Ajaleht Macias JM, Martin WJ, Lloyd CW.
Stability of morphine sulfate and meperidine hydrochloride in a parenteral nutrient formulation.
Am J Hosp Pharm 1985 ; 42: 1087-1094.
341 Ajaleht Baker DE, Yost GS, Craig VL, Campbell RK.
Compatibility of heparin sodium and morphine sulfate.
Am J Hosp Pharm 1985 ; 42: 1352-1355.
386 Ajaleht Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
398 Ajaleht Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557.
402 Ajaleht Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821.
404 Ajaleht Forman JK, Souney PF.
Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
Am J Hosp Pharm 1987 ; 44: 2298-2299.
405 Ajaleht Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
406 Ajaleht Smythe MA, Patel MA, Gasloli RA.
Visual compatibility of narcotic analgesics with selected intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 819-820.
492 Ajaleht Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Ajaleht Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
513 Ajaleht Xu QA, Trissel LA, Martinez JF.
Stability and compatibility of fluorouracil with morphine sulfate and hydromorphone hydrochloride.
Ann Pharmacotherapy 1996 ; 30: 756-761.
517 Ajaleht Letourneau M.
Visual compatibility of magnesium sulfate with narcotic analgesics.
Am J Hosp Pharm 1992 ; 49: 838-839.
519 Ajaleht Poggi GL.
Compatibility of morphine tartrate admixtures in polypropylene syringes.
Aust J Hosp Pharm 1991 ; 21: 316.
660 Ajaleht Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
813 Ajaleht Akkermann SR, Zhang H, Mullins RE, Yaughn K.
Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions.
Am J Health-Syst Pharm 1999 ; 56: 63-68.
814 Ajaleht Johnson CE, VandenBussche HL, Chio CC, Jacobson PA.
Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration.
Am J Health-Syst Pharm 1999 ; 56: 164-169.
815 Ajaleht Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL.
Stability of ondansetron hydrochloride and 12 medications in plastic syringes.
Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905 Ajaleht Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Ajaleht Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
932 Ajaleht Hor MMS, Chan SY, Yow KL, Lim LY, Chan E, Ho PC.
Stability of morphine sulphate in saline under simulated patient administration conditions.
J Clin Pharm Ther 1997 ; 22: 405-410.
1020 Ajaleht Zuber DEL.
Compatibility of morphine sulfate injection and prochlorperazine injection.
Am J Hosp Pharm 1987 ; 44: 67.
1041 Ajaleht Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1057 Ajaleht Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 Ajaleht Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1079 Ajaleht Stevenson JG, Patriarca C.
Incompatibility of morphine sulfate and prochlorperazine edisylate in syringes.
Am J Hosp Pharm 1985 ; 42: 2651.
1135 Ajaleht Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1228 Ajaleht Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381.
1232 Ajaleht Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1276 Ajaleht Shiffman E, Walker SE, Yoon T, Yeung M.
Stability and compatibility of morphine with bupivacaine.
Can J Hosp Pharm 1998 ; 51: 110-116.
1315 Ajaleht Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1341 Ajaleht Deeks T, Davis S, Nash S.
Stability of an intrathecal morphine injection formulation.
Pharm J 1983 ; 230: 495-497.
1410 Ajaleht Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Ajaleht Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Ajaleht Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1438 Ajaleht Souney PF, Solomon MA, Stancher D.
Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications.
Am J Hosp Pharm 1984 ; 41: 1840-1841.
1467 Ajaleht Sitaram BR, Tsui M, Rawicki HB, Lam S, Courage P, Sitaram M, Chapman CB.
Stability and compatibility of baclofen and morphine admixtures for use in an implantable infusion pump.
Int J Pharm 1995 ; 118: 181-189.
1490 Ajaleht Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1492 Ajaleht LeBelle MJ, Savard C, Gagnon A.
Compatibility of morphine and midazolam or haloperidol in parenteral admixtures.
Can J Hosp Pharm 1995 ; 48: 155-160.
1495 Ajaleht Nixon AR, O'Hare MCB, Chisakuta AM.
The stability of morphine sulphate and metoclopramide hydrochloride in various delivery presentations.
Pharm J 1995 ; 254: 153-155.
1496 Ajaleht Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428.
1512 Labor Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015
1516 Labor Ropivacaine (Naropeine®) - Summary of Product Characteristics
Mercury Pharmaceuticals Limited 2012
1603 Ajaleht Bergquist PA, Manas D, Hunke WA, Reed RA.
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611 Ajaleht Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625 Ajaleht Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Ajaleht Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1665 Ajaleht Öster Svedberg K, McKenzie J, Larrivee-Elkins C.
Compatibility of ropivacaine with morphine, sufentanil, fentanyl, or clonidine.
J Clin Pharm Ther 2002 ; 21: 39-45.
1678 Ajaleht Sitaram BR, Tsui M, Rawicki HB, Lam S, Sitaram M.
Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine.
Int J Pharm 1997 ; 153: 13-24.
1707 Ajaleht Trissel LA, Xu QA, Pham L.
Physical and chemical stability of low and high concentrations of morphine sulfate with bupivacaine hydrochloride packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 70-73.
1708 Ajaleht Xu QA, Trissel LA, Pham L.
Physical and chemical stability of low and high concentrations of morphine sulfate with clonidine hydrochloride packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 66-69.
1709 Ajaleht Trissel LA, Xu QA.
Physical and chemical stability of morphine sulfate 5 mg/ml and 50 mg/ml packaged in plastic syringes.
Int J Pharm Compound 2002 ; 6: 62-65.
1713 Ajaleht Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Ajaleht Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1754 Ajaleht Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1800 Ajaleht Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803 Ajaleht Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1810 Ajaleht Lee G, Sabra K, Doyle N, Malley GO.
Stability of morphine sulphate in P.C.A.s.
EJHP 2003 ; 1:1-3.
1869 Ajaleht Hildebrand KR, Elsberry DD, Hassenbusch SJ.
Stability and compatibility of morphine-clonidine admixtures in an implantable infusion system.
J Pain Symptom Manage 2003 ; 25, 5: 464-471.
1925 Ajaleht Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1944 Ajaleht Hartman CA, Faria CE, Mago K.
Visual compatibility of bivalirudin with selected drugs.
Am J Health-Syst Pharm 2004 ; 61: 1774.
1948 Ajaleht Classen AM, Wimbish GH, Kupiec TC.
Stability of admixtures containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system.
J Pain Symptom Manage 2004 ; 28, 6: 603-611.
1953 Ajaleht Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1964 Ajaleht Hartman CA, Baroletti SA, Churchill WW et al.
Visual compatibility of argatroban with selected drugs.
Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1968 Ajaleht Williams OA, Middleton M, Henderson P, Reilly CS.
Stability of morphine and droperidol separately and combined, for use as an infusion.
Hosp Pharm Pract 1992 ; 2, 9: 597-600.
1974 Ajaleht Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1982 Ajaleht Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2064 Ajaleht Nguyen-Xuan Tho, Griffiths W, Kern C, Van Gessel E, Bonnabry P.
Stability of morphine sulfate in polypropylene infusion bags for use in patient-controlled analgesia pumps for postoperative pain management.
Int J Pharm Compound 2006 ; 10: 69-73.
2086 Ajaleht Sharley NA, Burgess NG.
Stability and compatibility of alfentanil hydrochloride and morphine sulfate in poypropylene syringes.
J Pharm Pract and Res 2003 ; 33: 279-281.
2108 Ajaleht Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2123 Ajaleht Lee G, Sabra K.
Stability of morphine sulphate in ANAPA Plus ambulatory infusion device and PEGA infusion sets.
EJHP Science 2006 ; 12, 4: 76-80.
2196 Ajaleht Trissel LA, Trusley C, Ben M, Kupiec TC.
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during Y-site administration.
Am J Health-Syst Pharm 2007 ; 64, 11: 1209-1213.
2233 Ajaleht Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247 Ajaleht Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2251 Ajaleht Shields D, Montenegro R, Ragusa M.
Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration.
Neuromodulation 2005 ; 8, 4: 257-263.
2269 Ajaleht Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2298 Ajaleht Shields D.E, Aclan J, Szatkowski A.
Chemical stability of admixtures containing ziconotide 25 mcg/ml and morphine sulfate 10 mg/ml or 20 mg/ml during simulated intrathecal administration.
Int J Pharm Compound 2008 ; 12, 6: 553-557.
2305 Ajaleht Bianchi F, Ginggen A, Tardy Y.
Stability and compatibility of drug mixtures in an implantable infusion system.
Anaesthesia 2008 63, 9: 972-978.
2322 Ajaleht Donnelly R.F.
Physical Compatibility and Chemical Stability of Ketamine–Morphine Mixtures in Polypropylene Syringes.
Can J Hosp Pharm 2009 ; 62, 1
2350 Ajaleht Roy J.J, Hildgen P.
Stability of morphine-ketamine in 0.9% sodium chloride injection packaged in syringes, plastic bags and MEDICATION CASSETTE Reservoirs.
Int J Pharm Compound 2000 ; 4, 3: 225-228.
3012 Ajaleht Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3131 Ajaleht Donnely RF, Wong K, Spencer J.
Physical compatibility of high-concentration bupivacaine with hydromorphone, morphine and fentanyl.
Can J Hosp Pharm 2010 ; 63, 2: 154-155.
3152 Ajaleht Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3184 Labor
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005
3249 Ajaleht Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3279 Ajaleht Al-Tannak N.F, Cable C.G, McArthur D.A, Watson D.G
A stability indicating assay for a combination of morphine sulphate with levomepromazine hydrochloride used in palliative care.
J Clin Pharm Ther 2012 ; 37, 1: 71-73.
3434 Ajaleht Kistner C, Ensom M.H.H, Decarie D, Lauder G, Carr R.R.
Compatibility and Stability of Morphine Sulphate and Naloxone Hydrochloride in 0.9% Sodium Chloride for Injection.
Can J Hosp Pharm 2013 ; 66, 3 : 167-170.
3474 Labor Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3504 Labor Parecoxib (Dynastat®) - Summary of Product Characteristics
Pfizer 2012
3507 Labor Chirocaine - Summary of Product Characteristics
AbbVie 2013
3525 Labor Pethidine hydrochloride - Summary of product Characteristics
AMCO Amdipharm Mercury 2012
3531 Labor Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014
3571 Ajaleht Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3578 Labor Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3593 Labor Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics
Beacon Pharmaceuticals 2011
3595 Labor Aciclovir - Summary of Product Characteristics
Hospira 2009
3599 Labor Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
Amco Amdipharm Mercry 2013
3644 Labor Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3675 Labor Thiopental sodium - Summary of Product Characteristics
Archimedes Pharma UK Ltd 2015
3824 Ajaleht Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3828 Plakat Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Plakat So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3934 Labor Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
GlaxoSmithKline Laboratoire 2016
3948 Ajaleht Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
3964 Ajaleht Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3998 Ajaleht Robert J, Sorrieul J, Rossignol E, Beaussart H, Kieffer H, Folliard C, Dupoiron D, Devys C.
Chemical Stability of Morphine, Ropivacaine, and Ziconotide in Combination for Intrathecal Analgesia.
Int J Pharm Compound 2017 ; 21:4 :347-351
4051 Ajaleht Robert J, Sorrieul J, Kieffer H, Folliard C, Gibory V, Dupoiron D, Devys C.
Stability study of morphine and baclofen solution in polypropylene syringes.
Pharmaceutical Technology in Hospital Pharmacy 2017 ;2,4:173-180
4055 Ajaleht Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Ajaleht Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4303 Ajaleht Anderson C, MacKay M.
Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes.
Pharmacy 2015 3, 379-385.
4319 Ajaleht Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4380 Labor Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4389 Ajaleht Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4395 Plakat Hook R, Riss V, Neault A, Ma N, Law S, Walker S.E.
Stability of Morphine Solutions of 20, 40, 100 , 200 and 1,000 µg/mL in Syringes Following Dilution with 0.9% Sodium Chloride or D5W at Room Temperature (25°C).
Sunnybrook Health Sciences Centre 2020
4419 Ajaleht Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4434 Ajaleht Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4496 Ajaleht Sorrieul J, Robert J, Dupoiron D, Devys, C.
Stability Study of Admixtures Combining Ziconotide With Morphine or Sufentanil in Polypropylene Syringes.
Neuromodulation 2020 ; 24, 7: 1145-1156.
4528 Ajaleht Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4538 Ajaleht Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K.
Compatibility of pentoxifylline and parenteral medications.
Archives of Disease in Childhood 2020 ; 105: 395-397.
4543 Ajaleht Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4603 Ajaleht Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4650 Labor Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4669 Ajaleht Robert J, Sorrieul J, Dupoiron D, Jubier-Hamon S, Bienfait F, Visbecq A, Devys C.
Physicochemical Stability Study of the Morphine-Ropivacaine-Ziconotide Association in Implantable Pumps for Intrathecal Administration.
Neuromodulation 2021 : 1-16.
4730 Ajaleht Sorrieul J, Robert J, Vincent L, Andre M, Bourcier B, Bienfait F, Jubier Hamon S, Dupoiron D, Devys C.
Stability of Morphine Sulfate-Clonidine and Sufentanil-Clonidine Mixtures.
Neuromodulation 2022
4742 Ajaleht Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales